NUMI Begins Appearing on Brokerages, Available for Pre-market Orders on Some

Post published:May 20, 2020
Post category:News

Numinus is set to trade publicly today, with many wondering how and when they can add a position in the company.

Earlier today, we shared some updates that suggest LKYSD may be the US OTC ticker for NUMI. Now, we have some further information on the NUMI ticker itself.

The below brokerages are in alphabetical order.

CIBC Investor’s Edge

You can call in orders via the phone, after which they should appear in your open orders where the parameters can be adjusted.

Degiro

We expect Degiro to list NUMI, as they offer access to the TSXV exchange.

E-Trade

E-Trade user have reported that they are able to place pre-market orders for LKYSD, which appears to be the US OTC stock for Numinus.

Fidelity

NUMI is showing up on Fidelity’s International Trade Portal as NUMI:CA. Pre-market orders appear to be unavailable.

Interactive Brokers

For our international readers, IB offers an excellent way to access foreign exchanges, like TSXV.

Interactive Brokers is accepting pre-market orders for NUMI here (you must be logged in to access this page).

Questrade

Unsurprisingly, this Canadian brokerage is taking pre-market orders for NUMI. You can find the trade page under the ticker NUMI.VN.

TD Ameritrade

NUMI is now appearing on TD Ameritrade (you may have to check the Advanced Dashboard) but is not open for pre-market orders.

More to Follow

We are no longer updating this page, as trading has now commenced.

You can follow us on Twitter for the latest.

Tags: Numinus

Pα+ Psychedelic Bulletin #161: Numinus Shifts Focus to US; Algernon Makes DMT for Stroke Lead Asset; atai Pivots to IV IbogaineApril 17, 2024
Numinus’ Shifting Focus Toward U.S. Market Revealed via “Unauthorized Disclosure” • Algernon Pharmaceuticals Makes DMT Stroke Research Program Its Lead Asset • atai Pivots to IV Formulation of Ibogaine • Seaport Therapeutics Launches with $100m Series A, Pipeline Includes ‘Prodrug of a Non-Hallucinogenic Neuroplastogen’ • and more...
Developing Esketamine (Spravato) and Lessons for Psychedelic Drug Developers with Jaskaran SinghApril 12, 2024
Josh Hardman sits down with Jaskaran (‘Jaz’) Singh, who spearheaded the development of esketamine for treatment-resistant depression, now marketed as Spravato. We discuss how Singh’s early work assessing ketamine’s antidepressant effects at the National Institute of Mental Health (NIMH) encouraged him to move into industry; how his team decided to pursue esketamine; lessons learned that might be relevant for psychedelic drug developers; and his broader outlook on the field.
Natural Medicine Advisory Bulletin 10.1: Legislative UpdateApril 9, 2024
Vicente LLP reviews Senate Bill 24-198, the first legislative since the passing of SB-23-290 in 2023, which implemented the Natural Medicine Health Act.
MindMed’s ‘Total Elimination’ of Psychotherapy in LSD Study Stokes Debate Around Its Role in Psychedelic TherapiesApril 5, 2024
In March, MindMed scored an FDA Breakthrough Therapy Designation for its LSD-D-tartrate candidate (MM120) for generalised anxiety disorder (GAD). Here, Josh takes a closer look at the company's claim to have ‘eliminated’ psychotherapy from its Phase 2b study of MM120 and explores how a ‘Spravato-isation’ of psychedelic therapies is stoking broader debates around the contribution of psychotherapy in psychedelic therapies or ‘treatments’.
Natural Medicine Advisory Bulletin 10: March 2024April 4, 2024
Vicente LLP reviews the March 15th Colorado Natural Medicine Advisory Board meeting, where draft rules for Facilitator licensing and training were discussed.